EZH2 and endometrial cancer: For example, Lnc-DLEU2 can drive epithelial-mesenchymal transition and glycolysis in endometrial cancer through HK2 by competitively binding to miR-455 and by modulating the enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2)/miR-181 pathway [41].